Lyons TJ, French J
Headquarters USAF Human Systems Division,
Brooks Air Force Base, TX 78235.
Aviat Space Environ Med 1991
May;62(5):432-5
ABSTRACT
Modafinil, a novel stimulant which has several remarkable features that
distinguish it from other stimulants, has been developed by Lafon, a French
pharmaceutical company. Unlike the amphetamines, for example, modafinil is
reported to have minimal peripheral side effects at therapeutic doses. It also
appears to have a low abuse potential, does not interfere with normal sleep,
and does not seem to produce tolerance. Modafinil improves vigilance especially in
sleep-deprived subjects. It has been used clinically for up to 3 years in the
treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal
replacement for amphetamine in short-term operations in which fatigue might
threaten the successful completion of a mission. We recommend that military
laboratories experienced in studying sustained performance include modafinil
or perhaps a more selective alpha 1 receptor agonist in their investigations.
1. Modafinil augmentation
of antidepressant treatment
2. Modafinil children
with attention-deficit/hyperactivity disorder
3. Modafinil in
fibromyalgia treatment
4. Modafinil
efficacy in narcolepsy
5. Modafinil narcolepsy:
symptoms and management
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil
drug of choice for narcolepsy
8. Modafinil
in the treatment of
narcolepsy
9. Modafinil
effect on narcolepsy
10. Modafinil
a narcolepsy study
11. Modafinil
switching from narcolepsy drugs to modafinil
12. Modafinil
and naps as counter measures in sleep deprivation
13. Modafinil
as a treatment for excessive daytime sleepiness
14. Modafinil
use in a sleep deprivation experiment
15. Modafinil excessive sleepiness in Parkinson's disease
16. Modafinil the
unique properties of a new stimulant
17. Modafinil for
sustaining the alertness of helicopter pilots
18. Modafinil dosage
and safety
19. Modafinil
treatment of alcoholic organic brain syndrome
20. Modafinil
effect on melatonin, cortisol, and growth hormone
21. Modafinil
in obstructive sleep apnea-hypopnea syndrome
22. Modafinil
vs dextroamphetamine in treatment of adult ADHD
23. Modafinil
dopaminergic transmission mediates CNS stimulants
24. Modafinil
for daytime sleepiness in sleep apnea
25. Modafinil
treatment of residual excessive daytime sleepiness
26. Modafinil
amplification of cortical serotonin release
27. Modafinil for the treatment of
multiple sclerosis
